{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:40:40Z","timestamp":1777880440598,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["SAGE Open Medicine"],"published-print":{"date-parts":[[2014,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To describe the impacts of Virginia AIDS Drug Assistance Program\u2019s elimination of diabetes and hyperlipidemia medication on disease outcomes in people living with HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Data were collected on two groups of people living with HIV who were prescribed medications for diabetes and\/or hyperlipidemia; one group received medications from AIDS Drug Assistance Program (ADAP) and the other group received medications from another source. Data were collected for 13 months before and after the policy change. Diabetes, hyperlipidemia, and HIV control were compared using standard laboratory measures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>During the pre-policy-change time period, non-ADAP patients had better diabetes control than ADAP patients, but with multivariate analysis, ADAP status was no longer a statistically significant predictor. Otherwise, no significant differences between groups were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>ADAP patients had worse diabetes control compared to the non-ADAP group before the policy change. It is possible that this is due to the AIDS Drug Assistance Program population\u2019s poor access to non-HIV primary care, including care for diabetes. It is reassuring that, even during a time of flux in AIDS Drug Assistance Program resources, the AIDS Drug Assistance Program patients\u2019 co-morbid and HIV outcomes were not negatively impacted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2050312114532809","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T23:46:29Z","timestamp":1398815189000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of recent Virginia AIDS Drug Assistance Program policy changes on diabetes and hyperlipidemia control in people living with HIV"],"prefix":"10.1177","volume":"2","author":[{"given":"Kathleen A","family":"McManus","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Virginia, Charlottesville, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Relana","family":"Pinkerton","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Dillingham","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, VA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,4,29]]},"reference":[{"key":"bibr1-2050312114532809","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-011-1807-5"},{"key":"bibr2-2050312114532809","unstructured":"The Henry J. Kaiser Family Foundation. HIV\/AIDS policy fact sheet: AIDS drug assistance program, http:\/\/www.kff.org\/hivaids\/upload\/1584-11.pdf (2012, accessed 24 March 2013)."},{"key":"bibr3-2050312114532809","first-page":"350169","volume":"2013","author":"McManus K","year":"2013","journal-title":"AIDS Res Treat"},{"key":"bibr4-2050312114532809","unstructured":"National Alliance of State & Territorial AIDS Directors (NASTAD); Lefert A, McCloskey E and Pund B. National ADAP monitoring project annual report, http:\/\/nastad.org\/docs\/NASTAD-National-ADAP-Monitoring-Project-Report-Module-1-2013-1.pdf (2013, accessed 24 March 2013)."},{"key":"bibr5-2050312114532809","doi-asserted-by":"publisher","DOI":"10.1177\/17423953050010030301"},{"key":"bibr6-2050312114532809","unstructured":"Remley K. State health commissioner\u2019s letter to ADAP clinicians, http:\/\/www.vdh.state.va.us\/epidemiology\/DiseasePrevention\/Programs\/ADAP\/documents\/2010\/ADAP_letter_to_providers_12_3_10%20final.pdf (2010, accessed 24 March 2013)."},{"key":"bibr7-2050312114532809","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2012.0329"},{"key":"bibr8-2050312114532809","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.10.1179"},{"key":"bibr9-2050312114532809","volume-title":"Proceedings of the 16th conference on retroviruses and opportunistic infections","author":"Smith C","year":"2009"},{"key":"bibr10-2050312114532809","doi-asserted-by":"publisher","DOI":"10.2174\/1874192401105010049"},{"key":"bibr11-2050312114532809","doi-asserted-by":"crossref","unstructured":"The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction.\n                      N Engl J Med\n                      2003; 349(21): 1993\u20132003.","DOI":"10.1056\/NEJMoa030218"},{"key":"bibr12-2050312114532809","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.3728"},{"key":"bibr13-2050312114532809","doi-asserted-by":"publisher","DOI":"10.5888\/pcd10.120083"},{"key":"bibr14-2050312114532809","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-10-430"},{"issue":"36","key":"bibr15-2050312114532809","first-page":"1","author":"Fryar CD","year":"2010","journal-title":"NCHS Data Brief"}],"container-title":["SAGE Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050312114532809","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2050312114532809","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2050312114532809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:11:25Z","timestamp":1777594285000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2050312114532809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,1]]},"references-count":15,"alternative-id":["10.1177\/2050312114532809"],"URL":"https:\/\/doi.org\/10.1177\/2050312114532809","relation":{},"ISSN":["2050-3121","2050-3121"],"issn-type":[{"value":"2050-3121","type":"print"},{"value":"2050-3121","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,1]]},"article-number":"2050312114532809"}}